249 related articles for article (PubMed ID: 23909852)
1. Issues related to development of antiepileptogenic therapies.
Pitkänen A; Nehlig A; Brooks-Kayal AR; Dudek FE; Friedman D; Galanopoulou AS; Jensen FE; Kaminski RM; Kapur J; Klitgaard H; Löscher W; Mody I; Schmidt D
Epilepsia; 2013 Aug; 54 Suppl 4(0 4):35-43. PubMed ID: 23909852
[TBL] [Abstract][Full Text] [Related]
2. Gender issues in antiepileptogenic treatments.
Pitkänen A; Huusko N; Ndode-Ekane XE; Kyyriäinen J; Lipponen A; Lipsanen A; Sierra A; Bolkvadze T
Neurobiol Dis; 2014 Dec; 72 Pt B():224-32. PubMed ID: 24912075
[TBL] [Abstract][Full Text] [Related]
3. Development of new treatment approaches for epilepsy: unmet needs and opportunities.
French JA; White HS; Klitgaard H; Holmes GL; Privitera MD; Cole AJ; Quay E; Wiebe S; Schmidt D; Porter RJ; Arzimanoglou A; Trinka E; Perucca E
Epilepsia; 2013 Aug; 54 Suppl 4():3-12. PubMed ID: 23909849
[TBL] [Abstract][Full Text] [Related]
4. Epilepsy therapy development: technical and methodologic issues in studies with animal models.
Galanopoulou AS; Kokaia M; Loeb JA; Nehlig A; Pitkänen A; Rogawski MA; Staley KJ; Whittemore VH; Dudek FE
Epilepsia; 2013 Aug; 54 Suppl 4(0 4):13-23. PubMed ID: 23909850
[TBL] [Abstract][Full Text] [Related]
5. Antiepileptogenesis and disease modification: Clinical and regulatory issues.
French JA; Bebin M; Dichter MA; Engel J; Hartman AL; Jóźwiak S; Klein P; McNamara J; Twyman R; Vespa P
Epilepsia Open; 2021 Sep; 6(3):483-492. PubMed ID: 34270884
[TBL] [Abstract][Full Text] [Related]
6. Issues related to development of new antiseizure treatments.
Wilcox KS; Dixon-Salazar T; Sills GJ; Ben-Menachem E; White HS; Porter RJ; Dichter MA; Moshé SL; Noebels JL; Privitera MD; Rogawski MA
Epilepsia; 2013 Aug; 54 Suppl 4(0 4):24-34. PubMed ID: 23909851
[TBL] [Abstract][Full Text] [Related]
7. Proposal for a "phase II" multicenter trial model for preclinical new antiepilepsy therapy development.
O'Brien TJ; Ben-Menachem E; Bertram EH; Collins SD; Kokaia M; Lerche H; Klitgaard H; Staley KJ; Vaudano E; Walker MC; Simonato M
Epilepsia; 2013 Aug; 54 Suppl 4():70-4. PubMed ID: 23909855
[TBL] [Abstract][Full Text] [Related]
8. Disease modification in epilepsy: from animal models to clinical applications.
Barker-Haliski ML; Friedman D; French JA; White HS
Drugs; 2015 May; 75(7):749-67. PubMed ID: 25925798
[TBL] [Abstract][Full Text] [Related]
9. Antiepileptogenesis and disease modification: Progress, challenges, and the path forward-Report of the Preclinical Working Group of the 2018 NINDS-sponsored antiepileptogenesis and disease modification workshop.
Galanopoulou AS; Löscher W; Lubbers L; O'Brien TJ; Staley K; Vezzani A; D'Ambrosio R; White HS; Sontheimer H; Wolf JA; Twyman R; Whittemore V; Wilcox KS; Klein B
Epilepsia Open; 2021 Jun; 6(2):276-296. PubMed ID: 34033232
[TBL] [Abstract][Full Text] [Related]
10. Epilepsy biomarkers.
Engel J; Pitkänen A; Loeb JA; Dudek FE; Bertram EH; Cole AJ; Moshé SL; Wiebe S; Jensen FE; Mody I; Nehlig A; Vezzani A
Epilepsia; 2013 Aug; 54 Suppl 4(0 4):61-9. PubMed ID: 23909854
[TBL] [Abstract][Full Text] [Related]
11. Joint AES/ILAE translational workshop to optimize preclinical epilepsy research.
Galanopoulou AS; Simonato M; French JA; O'Brien TJ
Epilepsia; 2013 Aug; 54 Suppl 4():1-2. PubMed ID: 23909848
[No Abstract] [Full Text] [Related]
12. The holy grail of epilepsy prevention: Preclinical approaches to antiepileptogenic treatments.
Löscher W
Neuropharmacology; 2020 May; 167():107605. PubMed ID: 30980836
[TBL] [Abstract][Full Text] [Related]
13. Issues related to symptomatic and disease-modifying treatments affecting cognitive and neuropsychiatric comorbidities of epilepsy.
Brooks-Kayal AR; Bath KG; Berg AT; Galanopoulou AS; Holmes GL; Jensen FE; Kanner AM; O'Brien TJ; Whittemore VH; Winawer MR; Patel M; Scharfman HE
Epilepsia; 2013 Aug; 54 Suppl 4(0 4):44-60. PubMed ID: 23909853
[TBL] [Abstract][Full Text] [Related]
14. Neuroinflammatory targets and treatments for epilepsy validated in experimental models.
Aronica E; Bauer S; Bozzi Y; Caleo M; Dingledine R; Gorter JA; Henshall DC; Kaufer D; Koh S; Löscher W; Louboutin JP; Mishto M; Norwood BA; Palma E; Poulter MO; Terrone G; Vezzani A; Kaminski RM
Epilepsia; 2017 Jul; 58 Suppl 3(Suppl 3):27-38. PubMed ID: 28675563
[TBL] [Abstract][Full Text] [Related]
15. The National Institute of Neurological Disorders and Stroke (NINDS) Epilepsy Therapy Screening Program (ETSP).
Kehne JH; Klein BD; Raeissi S; Sharma S
Neurochem Res; 2017 Jul; 42(7):1894-1903. PubMed ID: 28462454
[TBL] [Abstract][Full Text] [Related]
16. Common data elements for preclinical epilepsy research: Standards for data collection and reporting. A TASK3 report of the AES/ILAE Translational Task Force of the ILAE.
Harte-Hargrove LC; French JA; Pitkänen A; Galanopoulou AS; Whittemore V; Scharfman HE
Epilepsia; 2017 Nov; 58 Suppl 4(Suppl 4):78-86. PubMed ID: 29105074
[TBL] [Abstract][Full Text] [Related]
17. When clinical trials make history: demonstrating efficacy of new antiepileptic drugs as monotherapy.
Perucca E
Epilepsia; 2010 Oct; 51(10):1933-5. PubMed ID: 20491875
[TBL] [Abstract][Full Text] [Related]
18. Prototype antiepileptic drug clinical development plan.
Kramer LD; Pledger GW; Kamin M
Epilepsia; 1993; 34(6):1075-84. PubMed ID: 8243359
[TBL] [Abstract][Full Text] [Related]
19. The Anticonvulsant Screening Program of the National Institute of Neurological Disorders and Stroke, NIH: History and Contributions to Clinical Care in the Twentieth Century and Beyond.
Porter RJ; Kupferberg HJ
Neurochem Res; 2017 Jul; 42(7):1889-1893. PubMed ID: 28275952
[TBL] [Abstract][Full Text] [Related]
20. Proceedings of the 15th Antiepileptic Drug and Device Trials Meeting: State of the Science.
Boada CM; French JA; Dumanis SB
Epilepsy Behav; 2020 Oct; 111():107189. PubMed ID: 32563052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
